Arcus Biosciences Q3 2026: Revenue Beat, EPS Miss, and Casdatifan in Focus
As seen on the 24/7 Wall St. homepage on November 4, 2026.
The Gilead collaboration is fading fast, with partnership reimbursements down to $12 million from $28 million a year ago, and the loss per share came in wider than expected because of it. A $694 million cash position funds operations into 2029, with PEAK-1 enrollment for casdatifan wrapping up in two to three months.
Continue ReadingShow less
Arcus Biosciences reported Q3 2026 revenue of $9 million, clearing the $8.27 million consensus estimate by about 8.8%. That headline beat, however, was accompanied by a loss per share of $1.00, missing expectations for a $0.89 loss.
The gap between the revenue beat and the earnings miss traces directly to the ongoing wind-down of the Gilead collaboration. Partnership reimbursements fell to $12 million from $28 million a year ago, sharply reducing the income that had historically cushioned Arcus's operating losses. Total revenue dropped 65% year over year, even as the company cleared the Wall Street bar on a dollar basis.
The net loss for the quarter narrowed modestly to $128 million from $135 million, and total operating expenses declined to $140 million. Some of that spending reduction reflects the wind-down of domvanalimab Phase 2 and 3 studies and the completion of enrollment in the PRISM-1 pancreatic cancer trial, partially offset by rising activity in the casdatifan Phase 3 program.
Sponsored
Casdatifan, the HIF-2α inhibitor Arcus is positioning as a potential standard of care across every line of clear cell renal cell carcinoma treatment, is now the company's central narrative. CEO Terry Rosen highlighted late-line monotherapy data showing a median overall survival of 35 months across 121 patients, alongside first-line and second-line combination results. The company has characterized the addressable market opportunity at $5 billion to $10 billion.
Enrollment in PEAK-1, the Phase 3 study of casdatifan plus cabozantinib in second-line kidney cancer, is expected to wrap up within two to three months. A second Phase 3 study, PEAK-20, targeting first-line patients, is set to begin by year-end, alongside several additional combination cohorts. Full-year 2026 GAAP revenue guidance stands at $70 million to $75 million.
With $694 million in cash on hand at quarter-end, supplemented by $288 million in gross proceeds from an October equity offering, management projects the balance sheet funds operations into 2029. That runway gives Arcus time to generate registrational data from both PEAK-1 and PEAK-20 before needing to return to capital markets, though the declining Gilead reimbursements will continue to pressure reported revenue in the near term.
Mentioned: RCUS